Progentec Diagnostics, Inc. Raises Funds to Support Advances in Lupus Detection and ManagementPublished: Wednesday, October 31, 2018 By: Associated Press
Progentec Diagnostics, Inc. (“Progentec”), a leader in the development of technological innovations in the field of diagnostics, today announced the completion of a second round of funding led by i2E, along with Chicago-based OCA Ventures and NMC Lifesciences, a leading global healthcare provider. The funding will help bring Progentec’s tool for identifying Lupus flare ups and a biomarker-based disease-activity index closer to commercialization. Technology created by the Oklahoma Medical Research Foundation (OMRF) is at the core of the platform being developed by Progentec.
Progentec today also announced the acquisition of LupusCorner, a leading patient-empowerment platform for people with systemic lupus erythematosus (SLE) and lupus nephritis. By integrating LupusCorner’s technology platform and data insights, Progentec is positioned to develop a first-in-class lupus-management platform. The founders of LupusCorner, Arif Sorathia and Brett Adelman, have joined Progentec and will help lead technology, outreach and growth initiatives.
Progentec’s technologies include highly accurate bio-marker based tests to diagnose disease before symptoms begin to show, as well as tests to monitor and predict disease activity levels in Lupus.
Read the full story here.